A New Wrinkle Relaxer That Works Faster and Longer Is Coming

At the IMCAS 2025 conference in Paris, Galderma presented new data on its yet-to-be-released injectable, RelabotulinumtoxinA, or Relfydess, which is generating buzz for its potential to work faster and last longer than existing wrinkle relaxers. According to the company, some patients in a phase IIIb trial—an advanced study conducted before regulatory approval—saw visible results as early as Day 1 after treatment. That could set it apart from current neurotoxin treatments, which typically take three to seven days to show effects, depending on the product.

How long does Relfydess last?

Beyond its rapid onset, the study also found that Relfydess maintained results for up to six months, with the median time to return to baseline severity for frown lines and crow’s-feet reported between 24 and 27 weeks. In comparison, most currently available neurotoxins last around three to four months before a touch-up is needed.

- Advertisement -

How It’s Different

What sets it apart, according to Galderma, is its formulation. Unlike traditional botulinum toxin treatments, which come in a powder form that must be mixed with saline before injection, Relfydess is a ready-to-use liquid. This innovation, developed with Galderma’s PEARL Technology, is designed to preserve the integrity of the active ingredient, minimize inconsistencies in dosing and streamline the injection process for practitioners.

What Galderma Says

“We are proud to share our latest RelabotulinumtoxinA data, which reaffirms the sustained clinical effect and patient satisfaction observed in our READY clinical trial program,” said Dr. Baldo Scassellati Sforzolini, Galderma’s Global Head of R&D, in a press release. “These findings, together with our proprietary PEARL Technology, reinforce RelabotulinumtoxinA as a safe, effective and innovative treatment option and uphold Galderma’s position at the forefront of aesthetic advancements.”

When will Relfydess be available?

Relfydess is not yet FDA-approved, and the company has not announced a U.S. launch timeline. However, Galderma is finalizing approval procedures in Europe, with availability expected in certain markets as early as next year. With increasing demand for faster, longer-lasting wrinkle relaxers, it’s one to watch.